ABSTRACT
The tumor susceptibility gene 101 (TSG101) encodes a multidomain protein that contains a UEV (ubiquitin e2 variant) domain at is N-terminus and a putative DNA-binding motif at its C-terminus. In addition to being a bona fide component of the ESCRT (endosomal sorting complexes required for transport) complex 1 and playing a critical role in endosomal sorting and trafficking, TSG101 has also been implicated in an array of cellular functions including, cytokinesis, protein ubiquitination, transcriptional regulation, cell cycle and proliferation, as well as viral budding. The major focus of this article is on the role of TSG101 in tumorigenesis.
INTRODUCTION: INITIAL DISCOVERY AND CONTROVERSY
TSG101, originally known as CC2, was initially identified as a putative coiled-coil domain-containing protein that interacts with stathmin in a yeast two-hybrid screen in 1995 (1). Shortly after, the full-length TSG101 was cloned and its initial function was revealed as a potential tumor suppressor from a controlled homozygous functional knockout screen. Inactivation of TSG101 in NIH3T3 mouse fibroblasts led to focus formation in monolayer cell cultures, anchorage independent growth in soft-agar, and in vivo tumor formation in nude mice. Interestingly, the same study also showed that overexpression of the TSG101 also resulted in cellular transformation as evident from focus formation and colony growth in soft agar (2). Subsequent studies mapped human TSG101 to chromosome 11, subbands p15.1-15.2, a region showing loss of heterozygosity (LOH) in a variety of human malignancies. Moreover, it was found that seven of the fifteen uncultured primary human breast carcinomas had intragenic TSG101 deletions, on the basis of the presence of truncated transcripts observed RT-PCR and Southern blot analysis of PCR products of genomic DNA, while no TSG101 abnormalities were observed in matched normal breast tissue from these breast cancer patients (3). Immediately after the original publication showing that TSG101 was often mutated in human breast cancers, several studies using larger numbers of tumor samples failed to detect intragenic TSG101 deletions. Lee and Feinberg analyzed 72 samples of primary breast cancer samples. Identical digestion patterns were observed for all tumors, matched and unrelated normal tissues by Southern hybridization of genomic DNA. Analysis of 46 breasttumor samples and matched blood control samples, as well as multiple breast cancer cell lines, by Southern blot experiments, failed to confirm that TSG101 gene undergoes large rearrangements in a significant portion of breast tumors and breast cancer cell lines as originally suggested (4).
Several additional follow-up studies, analyzing genomic DNA and mRNA isolated from cancer and normal samples, verified the occurrence of "aberrant TSG101 transcripts" but again failed to detect significant intragenic deletions, insertions or mutations of TSG101 (5 -7). It was suggested that these apparently aberrant transcripts were the products of either PCR artifacts (7) or alternative/aberrant splicing variants and present in both cancer and normal tissues (6).
However, further comparative analysis of human and mouse TSG101 genes revealed additional introns within the human TSG101 gene and determined that these shorter TSG101 transcripts were not aberrant splicing variants, but true alternative splicing variants generated exclusively by exon skipping (8). These convincing results called into question the existence of TSG101 mutants in breast cancer, as well as the role of TSG101 as a tumor suppressor, which led to the retraction of the original publication (9).
TSG101 STRUCTURE AND FUNCTION
Human TSG101 protein is 390 amino acid residues in length and contains four known structural motifs: the N-terminal UEV domain, followed by a prolinerich region (PRR), a coiled coil (CC) region, and a Cterminal α-helical/steadiness box (SB) domain. Each of these motifs possesses distinct structure and functionalities that render TSG101 versatile in cellular functions ( Figure  1 ).
The UEV domain
The UEV domain of human TGS101 encompasses the first 145 amino acid residues. It shows significant sequence homology to ubiquitin E2 ligases. While catalytically inactive as it lacks the active-site cysteine, replaced by a tyrosine residue (10, 11), TSG101 UEV domains retains the ability to bind ubiquitin, which is essential for TSG101's functions in sorting protein cargo into multivesicular bodies (MVBs) and late endosomal compartments and facilitating viral budding. The threedimensional structure of the TSG101 domain has been solved by both NMR and X-ray crystallographic techniques (12, 13) . The TSG101 UEV domain folds into a typical ubiquitin-conjugating (UBC)-like structure (E2 fold) with four α-helices packed against one side of a four stranded anti-parallel β-sheet. The X-ray crystal structure of TSG101 UEV-ubiquitin complex reveals that ubiquitin molecule binds to a concave surface on the other side of the β-sheet to form a highly solvated interface that buries a 1,250 Å 2 solvent accessible surface area (14) . The crystal structures of the free and ubiquitin-bound TSG101 UEV are essentially identical, with an RMSD (root-mean-square deviation) of 2 Å that exclusively involves amino acid residues Asp45 and Asp46 in the β-hairpin formed by strand 1/2 (13).
In addition to binding ubiquitin, the TSG101 UEV domain also binds P(T/S)AP sequence motifs in both viral and cellular proteins. For example, interaction of TSG101 UEV with the PSAP motif located within an intrinsically flexible region of the Hrs subunit of ESCRT-0 is believed to responsible for the recruitment of the ESCRT-1 complex by ESCRT-0 (15). Again, both NMR and X-ray crystal structures of TSG101 UEV-PTAP peptide complexes are available (16, 17) . The solution structure of TSG101 UEV domain in complex with a nineresidue PTAP peptide from the late domain of HIV-1 Gag protein shows that the PTAP peptide binds to a bifurcated groove independent of the ubiquitin surface with each of the PTAP residues making extensive contacts with the protein. Unlike the binding of ubiquitin, PTAP binding induces noticeable conformational changes in TSG101 UEV (16) . While the crystal structure TSG101 UEV-PTAP complex qualitatively confirms the overall binding architecture of the peptide, detailed interactions between the peptide and the protein differs significantly between the two structures. The peptide backbone between P and T is flipped 180° between the crystal and the averaged NMR structure. The peptide connecting T and A is also in a sharply different orientation (17) . At present, the causes of these structural differences are not entirely clear. Nonetheless, these structural data demonstrate that TSG101 UEV can simultaneously interact with both ubiquitin and the PTAP motif from different protein partners or from the same protein. These interactions are essential for TSG101 to participate in different cellular processes, such as the organization of the ESCRT complex, cargo recruitment, transcriptional regulation and cytokinesis (14, 18, 19) .
The proline-rich region (PRR)
The proline-rich region of TSG101, spanning approximately 70 residues with a 30% Pro content, connects the UEV domain to the core of ESCRT-1 complex. Presumably, the TSG101 PRR is unstructured and not as well studied as the UEV domain. The function of the PRR was not revealed until recently (20, 21) . It was reported that a proline-rich sequence, 154 QATGPPNTSYMPG 166 , within the PRR of TSG101 competes with a similar proline-rich sequence on ALIX (ALG-2-interacting protein X), an ESCRT associated protein, for binding to the central hinge region of CEP55A (21) . CEP55A is a mid-body protein required for abscission (22) . The presence of ESCRT-I and ALIX lead to further recruitment of the ESCRT-III complexes, which are believed to possess membrane scission activity and to be responsible for cell abscission during cytokinesis (19) . Depletion of TSG101 and ALIX inhibits cell abscission, suggesting that both proteins are required for cytokinesis (20) . In addition to CEP55A, TSG101 PRR also binds ALG-2 (apoptosis-linked gene 2), a dimeric Ca 2+ -binding EF hand protein, in a Ca 2+ -dependent manner (23) . While the binding site for ALG-2 on ALIX has been mapped to overlaps with the CEP55-binding sequence described above (24) , the corresponding sequence in TSG101 has not been mapped in detail. Nor has the function of TSG101-ALG2 interaction been determined.
The coiled-coil (CC) region
The CC region was initially identified in a yeasthybrid screen for its ability to bind stathmin, a cytosolic phosphoprotein implicated in tumorigenesis (1). Crystallographic analyses of the yeast ESCRT-1 complex, which is conserved from yeast to humans, reveals that the CC region of Vps23, the yeast ortholog of TSG101, interacts with Vps37 and Mvb12 to form a 130 Å long, rigid stalk of triple coiled helices (25) . These structural studies confirm that the CC region of TSG101 is essential for the structural integrity of the ESCRT-1 complex. In addition, it has been reported that the CC domain is essential for TSG101-mediated suppression of ligandinduced transactivation of estrogen receptor and other nuclear hormone receptors (26) . Further studies have demonstrated that TSG101 CC interacts with Daxx, a Fas interacting protein and transcription regulator, and colocalizes with Daxx in the nucleus, where TSG101 and Daxx cooperatively repress glucocorticoid receptormediated transcriptional activity (27) . Moreover, a TSG101 isoform without the CC resulted from alternative slicing has been shown to be expressed exclusively in Burkitt's lymphoma cells and non-Hodgkin's lymphomas, but not in normal cells (28, 29) .
The C-terminal α-helical/steadiness box (SB) domain
The C-terminal α-helical/Steadiness box (SB) domain of Vps23/TSG101, the N-terminal half of Vps28, and the C-terminal half of Vps37 form the headpiece of the ESCRT-1 complex core (30, 31) . The SB domain forms a hairpin structure consisting of two long antiparallel α helices. Despite a lack of detectable sequence similarity, the three subunits of the ESCRT-1 headpiece assume a strikingly similar overall structure and are arranged sideby-side at nearly identical ~30° angles with Vps23 in the middle making direct interactions with the Vps28 subunit on one side and Vps37 subunit on the other. There is no direct contact between Vps28 and Vps37 (30, 31) . These results suggest that the SB domain, along with the CC domain, plays an important role in maintaining ESCRT-1 stability.
Besides being a critical structural component of the ESCRT-1 complex, the SB domain also plays an important role in maintaining the homeostasis of cellular levels of TSG101. Considering that both depletion and overexpression of TSG101 lead to oncogenic transformation and abnormal cell growth, it is not surprising that the levels of TSG101 are controlled within a narrow range in normal cells. Feng and colleagues report that the TSG101 protein is maintained at a steady-state level in cultured murine and human cells. Ectopic expression of TSG101 results in a down-regulation of endogenous TSG101. It is further revealed that the cellular level of TSG101 is controlled in an auto-regulatory manner through a posttranslational process involving a "steadiness box," located near TSG101's COOH-terminal end (32) . Subsequent studies demonstrate a mechanism of TSG101 autoregulation that involves Tal (TSG101-associated ligase), a novel ring-finger containing E3 ubiquitin ligase (33) . Tal contains an N-terminal leucine-rich repeat (LRR), followed by an ezrin-radixinmoezin (ERM) domain, a coiled-coil (CC) region, an α sterile alpha motif (SAM), and a C-terminal RING finger (RF), as well as a tandem PT(S)AP motif immediately N-terminal to the RF. Tal interacts with TSG101 in a bimodal fashion, while the PT(S)AP motif recognizes the UEV domain of TSG101 the central region of Tal binds to the SB domain. Monoubiquitination of TSG101 at multiple lysine residues at the C-terminal SB domain by Tal shuttles TSG101 from membrane bound fractions to cytoplasm and inactivates its cargo sorting activities such as receptor tyrosine kinase internalization and viral budding (34) . Subsequent studies reveal additional Tal functions in controlling TSG101 protein stability, where Tal polyubiquitinates lysine residues in the Cterminus SB domain of TSG101, therefore targeting TSG101 for proteasome-mediated degradation (33) . Complex formation with Vps28 or Vps37 as described above for the ESCRT-1 headpiece prevents Tal-mediated polyubiquitination presumably by blocking the access of the lysine residues within the SB domain. While essential for maintaining cellular homeostasis of TSG101 level, polyubiquitination of the SB domain by Tal does not seem to be important for other ESCRT related TSG101 functions (33) .
Another ring finger containing E3 ubiquitin ligase, Mahogunin, has been reported to interact with TSG101 in a similar fashion as Tal. Mahogunin binds to TSG101 UEV domain via its PSAP motif and catalyzes monoubiquitination of TSG101 at multiple lysine sites. However, it is not clear if Mahogunin and Tal target the same lysine residues located within the SB domain. In addition, Mahogunin does not polyubiquitinate TSG101, and ectopic expression of Mahogunin does not result in TSG101 degradation (35) .
TSG101 ROLE IN CANCER
Since the initial discovery and debate of TSG101 as a candidate tumor suppressor gene, major efforts have been devoted to reexamine the role of TSG101 in tumorigenesis. While the subject remains controversial, significant amount of literature now describes TSG101 as a tumor progression enhancer in various types of cancers.
TSG101 and Breast Cancer
The involvement of TSG101 in cancer was initially reported in breast cancer, one of the most studied human cancer types. Li, et al in 1997 reported that abnormal truncation of the coiled-coil domain of TSG101 could be detected in 7 out of 15 breast cancer samples. This high frequency of coiled-coil domain deletion led to the proposal of TSG101 as a tumor suppressor (3), which seems to consistent with the fact that TSG101 gene is located on chromosome 11, subbands p15.1-15.2, a region associated with LOH in breast cancer (36) . However, as discussed earlier, further studies failed to verify intragenic deletions, insertions or mutations of TSG101 in breast tumors (4 -7). In fact, targeted deletion of Tsg101 in mouse embryonic fibroblasts does not lead to increased proliferation and cellular transformation and actually results in growth arrest at G1/S transition and cell death (37) . In addition, studies using mammary gland-specific knockout mice show that Tsg101 is essential for the growth, proliferation, and survival of mammary epithelial cells and Tsg101 deficient mice do not develop mammary tumors after a latency of 2 years (38) . Results based on three double knock-out models (Tsg101/p53, Tsg101/p21, and Tsg101/p19
Arf ) further reveal that Tsg101 is essential for cell survival regardless of the status of p53, p21 and p19
Arf (39) . Taken together, these studies convincingly demonstrate that TSG101 is required for normal cell function of embryonic and adult tissues but not a tumor suppressor for breast cancer.
Further challenging the notion that TSG101 is a potential breast cancer tumor suppressor, it appears that the expression levels of TSG101 in primary human breast carcinomas are upregulated (40 -42) . On the other hand, gene silencing of TSG101 via RNAi in MDA-MB-31 cells resulted in growth inhibition and cell cycle arrest at the G1/S checkpoint. In addition, TSG101 downregulation also suppressed both colony formation potential and the migratory capability of the cancer cells (43) . Similar results were recently reported using MCF-7 cells (44) . To test if Tsg101 has oncogenic properties in vivo, Oh et al. generated transgenic mice that overexpressed Tsg101 in the developing mammary gland. While the mammary gland of females overexpressing exogenous Tsg101 developed normally throughout the reproductive cycle, the ectopic expression of Tsg101 led to increased levels of phosphorylation Erk1/2 and stat3, and slightly increased the susceptibility of mammary epithelia toward malignant transformation in aging females. These results suggest that Tsg101 protein possesses only weak oncogenic properties, i.e., instead of tumor initiation, Tsg101 is more likely playing a role in the progression of a subset of spontaneously arising breast cancers (41).
TSH101 and Ovarian Cancer
Ovarian cancer is another common gynecological tumor where deletion of both regions at 11p15.5-15.3 and 11p15.1 is strongly associated with high grade nonmucinous epithelial ovarian cancer (45) . Similar to breast cancer, truncated TSG101 transcripts of the TSG101 is frequently observed in ovarian cancer (46 -48) . Again, these truncated TSG101 transcripts most likely represent splice variants as there is no evidence of genomic deletions in the TSG101 gene in ovarian cancer (46, 47, 49) .
Functional proteomic analysis of geneticallydefined human ovarian cancer models reveals that TSG101 is up-regulated in human ovarian epithelial cells expressing oncogenic HRAS or KRAS (50, 51) . Suppressing TSG101 by siRNA in ovarian cancer SKOV-3 cells led to G 2 /M arrest, growth inhibition and cell death. The levels of hypoxia inducible factor 1α (HIF-1α) and CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), two closely related transcriptional factors important for cell growth and survival, were markedly reduced after TSG101 knockdown (50) . Concurrent with down-regulation of CITED2 and HIF-1α, the mRNA and protein levels of the cyclin-dependent kinase inhibitor p21 are dramatically increased (52) . When ectopically implanted in athymic nude mice, SKOV-3 cells transfected with TSG101 siRNA induced significantly smaller tumors in vivo than those from SKOV-3 cell treated with control non-specific siRNA (50) .
Consistent with the finding in genetically-defined human ovarian cancer models, Immunoanalysis using ovarian cancer samples and micro-tissue array containing 422 cases of primary ovarian cancer samples revealed elevated TSG101 levels in more than 70% of human ovarian carcinomas. While normal human ovarian surface epithelium did not show significant expression for TSG101, the expression of TSG101 was increasingly positive in borderline tumors, low grade and high grade carcinomas compared to normal human ovarian surface epithelium. Compared to other histotypes, serous carcinoma, poorly differentiated carcinomas and malignant mixed mullerian tumors expressed higher levels of TSG101. There is a positive correlation between the grade and stage of the cancer and the levels of TSG101 expression in EOC. Moreover, the levels of TSG101 expression have significant impacts on the prognostic outcomes. The 5-year survival rate for ovarian cancer patients with low TSG101 expression is about 53% while only 33% patients with high levels of TSG101 survive more than 5 years (52) . Taken together, these results suggest that elevated TSG101 is associated with poor prognosis and a potential therapeutic target for ovarian cancer. Indeed, a recent study showed a time-dependent down-regulation of TSG101 in human ovarian cancer A2870 cells in response to Gleevec chemotherapeutic treatment, suggesting TSG101 expression level may represent an important index of drug efficacy for Gleevec in ovarian cancer (53) 
TSG101 Cervical Cancer
Unlike that of breast cancer or ovarian cancer, the development of cervical cancer is strongly associated with human papillomavirus (HPV) infection (54) . While HPV infection is a necessary factor in the development of almost all cases of cervical cancer (55), the development of cervical cancer is a rare event that requires additional genetic and epigenetic alterations. Similar to breast and ovarian cancers, LOH for alleles on chromosome 11 has been reported for cervical carcinoma (56, 57) . Aberrant splicing of TSG101 was also detected in both primary cancer samples and immortalized cell lines (58 -62). However, no mutation and intragenic deletion was observed in both normal and malignant cells, and there is no evidence of direct connection between truncated transcript and cancer progression (59, 61) . On the other hand, a recent report suggests that the expression level of TSG101 is downregulated in cervical cancer (63) . This apparent downregulation of TSG101 observed in cervical cancer is likely a direct consequence of HPV infection as decreased TSG101 levels are observed in non-tumor cervical cell infected by HPV16. Since HPV infection has been shown to cause epigenetic changes in cervical cancer (64) , one possibility is that the promoter of TSG101 is hypermethylated to inhibit its expression. However, methylation analysis of TSG101 promoter suggests that TSG101 down-regulation in cervical cancer cells is not regulated by epigenetic events (63) . Therefore, the mechanism of TSG101 down-regulation in cervical cancer remains unclear.
TSG101 and Prostate Cancer
As in breast and ovarian cancers, abnormal splicing variants of TSG101 were frequently observed (65, 66) . For example, analysis of 15 cases of primary and metastatic prostate cancer led to the detection of transcripts with deletions in nine samples (65) . Like breast cancer and ovarian cancer, prostate cancer is also sex hormone related. The development of this cancer type is closely associated with the functions of androgen and its receptor (AR). Sun and colleagues reported that TSG101 can interact with AR to suppress it ligand-induced transcriptional activation. Instead of a direct binding, interaction between AR and TSG101 was shown to be mediated by a transcription coactivator, CBP/p300, which is capable of binding to TSG101 both in vitro and in vivo (67) . In contract to the initially reported role of AR transcription suppression, a more recent investigation revealed that TSH101 functioned as a coactivator of the AR by promoting it monoubiquitination (18) . This is consistent with the finding that reduction of TSG101 protein has a negative impact on prostate tumor cell growth (43) .
As a member of Vps protein family, TSG101 is an integral component of the prostasomes, exosome-like vesicles released by human prostate epithelial cells (68) . Prostasomes have been implicated in playing roles in prostate cancer progression (69) and may be used as a biomarker for prostate tumor metastasis (70) . Prostasomes released from prostate cancer cells contain high levels of protein kinases and concurrent lower ATPase activity which may affect interaction between cancer cell and its microenvironment through increased phosphorylation (71) . While the exact role of TSG101 in prostasomes formation and secretion is not clear, a recent study shows that TSG101 is important for increased release of endosomelike vesicles in human prostate cancer cells response to radiation treatment. Moreover, these TSG101 containing exosome-like microvesicles were enriched in B7-H3 protein, a diagnostic marker for prostate cancer (72) .
TSG101 and Lung Cancer
Aberrant splicing but no intragenic deletion of TSG101 is a common event in different cancer types, including lung cancer (46, 73) . Normal and shortened TSG101 transcripts were detected in 89% of small cell lung carcinoma (SCLC) cell lines while only the full-length TSG101 transcript was detected in normal tissues, primary non-small cell lung carcinoma (NSCLC) specimens, and the majority of NSCLC cell lines. Single strand conformational polymorphism (SSCP) analysis and direct sequencing of TSG101 cDNAs failed to detect mutations or deletions, suggesting suggest that TSG101 is not mutated in lung cancer (74) .
Contradicting results have been reported regarding the expression level of TSG101 in lung cancer (75, 76) . TSG101 was identified from a cDNA library constructed from Anip973, a highly metastatic lung adenocarcinoma cell line, to be able to promote colony formation and anchorage-independent growth on soft agar when transfected in NIH3H3 cells. Further analysis reveals that TSG101 is overexpressed in all fifteen lung cancer cell lines and five lung cancer tissues examined as compared to matching normal lung tissue. Ectopic expression of TSG101 cDNA in A549, a lung adenocarcinoma cell line, resulted in an increased cell proliferation (75) . These results suggest that TSG101 is unlikely a primary tumor suppressor gene, but is capable of promoting cell growth the malignant phenotype in NIH3T3 and lung cancer cells. However, Chang and colleagues reported that TSG101 level is decreased in human lung cancer samples (76, 77) . Downregulation of TSG101 protein was correlated with the upregulation of Notch 3 receptor in lung cancer (78) . The exact reason for this apparent discrepancy is not obvious. To understand the role of TSG101 in lung cancer, more careful studies with larger sample sizes are required.
Conclusion and Perspectives
TSG101 is a versatile protein that has been implicated in multiple cellular functions, including but not limited to, endosomal sorting and trafficking (79 -82), transcriptional regulation (83, 84) , cell cycle and proliferation (37, 38, 85 -87) , protein ubiquitination regulation (88, 89) , and cytokinesis (20, 21, 90, 91) . While initially discovered as negative regulator for tumorigenesis, accumulating evidence now describes TSG101 as a positive modulator of cancer progression. Consistent with this notion, overexpression of TSG101 has been reported in most cancer types, in addition to the five discussed above such as, colorectal carcinoma (92), gastric carcinoma (93), papillary thyroid carcinoma (94, 95), gallbladder adenocarcinoma (96) , and multi-drug resistant human gastric adenocarcinoma cell (97) . The ability of TSG101 to serve both positive and negative roles in cellular homeostasis places it alongside with an increasing family of proteins that can regulate cellular functions in apparently opposing manners under different physiological contexts. The challenge will be to define precisely how TSG101 exerts its oncogenic properties in cancer development. Important questions include: Which particular cellular function is critical for TSG101's role in cancer? Does TSG101 play a similar role in all cancer types or is its functions in cancer tissue-specific? What are the roles of TSG101 splicing variants and how are they regulated? Answers to these questions will not only clarify the current controversy within the field but may also provide new diagnostic and/or therapeutic tools for cancer.
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